Hydroa vacciniforme
disease diseaseOn this page
Also known as hV
Summary
Hydroa vacciniforme (MONDO:0018024) is a disease and 9 clinical trials. Top therapeutic interventions include nitrous acid. A subtype of dermatitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 1 000 000 (United Kingdom) [Orphanet-validated]
- Phenotypes (HPO): 18
- Clinical trials: 9
Clinical features
Epidemiology
Prevalence records
2 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-9 / 1 000 000 | 0.34 | United Kingdom | Validated |
| Point prevalence | 1-9 / 1 000 000 | Europe | Not yet validated |
Signs & symptoms
Clinical features (HPO)
18 HPO clinical features (Orphanet curated; top 18 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0000992 | Cutaneous photosensitivity | Obligate (100%) |
| HP:0032381 | Hydroa vacciniforme | Obligate (100%) |
| HP:0100699 | Scarring | Obligate (100%) |
| HP:0025300 | Malar rash | Very frequent (80-99%) |
| HP:0033700 | Papulovesicular eruption | Very frequent (80-99%) |
| HP:0000491 | Keratitis | Occasional (5-29%) |
| HP:0000613 | Photophobia | Occasional (5-29%) |
| HP:0000964 | Eczematoid dermatitis | Occasional (5-29%) |
| HP:0002315 | Headache | Occasional (5-29%) |
| HP:0007663 | Reduced visual acuity | Occasional (5-29%) |
| HP:0009926 | Epiphora | Occasional (5-29%) |
| HP:0010783 | Erythema | Occasional (5-29%) |
| HP:0025337 | Red eye | Occasional (5-29%) |
| HP:0031190 | Superficial dermal perivascular inflammatory infiltrate | Occasional (5-29%) |
| HP:0031541 | Linear C3 deposits along the epidermal basement membrane zone | Occasional (5-29%) |
| HP:0033834 | Malaise | Occasional (5-29%) |
| HP:0100585 | Telangiectasia of the skin | Occasional (5-29%) |
| HP:0010473 | Porphyrinuria | Excluded (0%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | hydroa vacciniforme |
| Mondo ID | MONDO:0018024 |
| MeSH | D006837 |
| Orphanet | 330058 |
| ICD-11 | 2053786485 |
| NCIT | C84766 |
| SNOMED CT | 200837006 |
| UMLS | C0020241 |
| MedGen | 5661 |
| GARD | 0009654 |
| Is cancer (heuristic) | no |
Also known as: hV
Disease family
This is a subtype of dermatitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › hydroa vacciniforme
Related subtypes (32): spongiotic dermatitis, atopic eczema, psoriasis, contact dermatitis, urticaria, acneiform dermatitis, acrodermatitis, folliculitis, granuloma annulare, granulomatous dermatitis, lichen planus, neurodermatitis, neurotic excoriation, parapsoriasis, pityriasis rosea, seborrheic dermatitis, acanthosis nigricans, dermatosis papulosa nigra, lichen sclerosus et atrophicus, vitiligo, acne, porphyria cutanea tarda, dermatomyositis, acute generalized exanthematous pustulosis, autoimmune bullous skin disease, cutaneous vasculitis, skin infection, intertrigo, lipodermatosclerosis, exfoliative dermatitis, radiodermatitis, food dermatitis
Subtypes (1): hydroa vacciniforme, familial
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 9.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 6 |
| Not specified | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07528053 | PHASE1 | NOT_YET_RECRUITING | A Phase 1 Clinical Study of BW-20805-2-1001 in Healthy Participants |
| NCT07584876 | PHASE1 | NOT_YET_RECRUITING | A Phase 1 Clinical Study in Healthy Participants |
| NCT00105222 | PHASE1 | TERMINATED | Effect of Nitrite on Exercise Physiology and Metabolism |
| NCT00106769 | PHASE1 | COMPLETED | Vaccine to Prevent West Nile Virus Disease |
| NCT00340574 | PHASE1 | COMPLETED | Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark) |
| NCT00944931 | PHASE1 | COMPLETED | High-Density Direct Current Brain Polarization |
| NCT00105118 | Not specified | COMPLETED | Effect of Transcranial Magnetic Stimulation on Memory |
| NCT00105131 | Not specified | COMPLETED | Genetic Characterization of Parkinson’s Disease |
| NCT00106795 | Not specified | COMPLETED | Relationship Between Fatigue and Mitochondrial Damage in Patients With HIV/AIDS |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| NITROUS ACID | 4 | 2 |
Related Atlas pages
- Drugs: Nitrous Acid